{
  "news": [
    {
      "headline": "Sun Pharma Q3 FY25 Net Profit Rises 15% to ₹2,903 Crore",
      "text": "Sun Pharmaceutical Industries reported a 15% year-on-year increase in consolidated net profit for Q3 FY25, reaching ₹2,903 crore. This growth was driven by strong domestic sales, which rose 14% to ₹4,300 crore, and a 17.5% increase in global specialty pharmaceutical sales to $370 million. Total revenue grew 10.5% to ₹13,675 crore."
    },
    {
      "headline": "Sun Pharma's Global Specialty Segment Boosts Margins",
      "text": "The company's high-margin global specialty pharmaceutical segment, including treatments for alopecia and psoriasis, reported a 17.5% jump in sales to $370 million, contributing 21% to total sales. Analysts note that the increasing contribution from global specialty drugs is a key positive for Sun Pharma and will continue to boost margins in the near term."
    },
    {
      "headline": "Sun Pharma's U.S. Sales Show Modest Growth Amidst Competitive Pressures",
      "text": "Despite the overall positive performance, Sun Pharma's sales in the U.S. market increased by only 0.7% in Q3 FY25. The company, like many Indian generic drugmakers, faces stiff competition and pricing pressures in the U.S., which have been weighing on profit margins."
    },
    {
      "headline": "Sun Pharma's Domestic Market Remains Strong",
      "text": "India continues to be Sun Pharma's largest revenue-generating region, accounting for approximately 31% of total sales. In Q3 FY25, domestic sales rose 14% to ₹4,300 crore, surpassing the 11% increase observed in the previous quarter, indicating robust demand in the local market."
    }
  ]
}
